PDRadiopharma’s Techne® Pyrophosphate Injection Approved For National Health Insurance Listing In Japan
PDRadiopharma's Techne® Pyrophosphate Injection joins Japan's NHI list; launch on Feb 3, 2025, for advanced bone disease diagnostics.
Today, PDRadiopharma Inc. announced that its Techne® Pyrophosphate Injection has been added to Japan’s National Health Insurance (NHI) drug price list. The product is set for market launch on February 3, 2025.
Techne® Pyrophosphate Injection is a radiopharmaceutical designed for diagnosing bone diseases through bone scintigraphy. PDRadiopharma has previously marketed the Techne® Pyrophosphate Kit, which contains technetium-99m pyrophosphate and is used for diagnosing both bone and cardiac diseases via scintigraphy. Previously, healthcare professionals had to mix the kit with sodium pertechnetate (99mTc) injection for use in bone disease diagnosis to simplify the preparation process and reduce radiation exposure for medical staff. PDRadiopharma received approval in August 2024 for a pre-mixed formulation, which will be available starting February 3, 2025.
PDRadiopharma remains committed to improving healthcare by developing innovative pharmaceutical solutions that enhance patient care and well-being, particularly in safely handling radiopharmaceuticals.
Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion